Onward TherapeuticsFactsSource Subscribe

Funding round

Funding round for Onward Therapeutics led by CDIB Capital Healthcare Ventures

Oncology drug development (biotech) · Taipei, TW

$900mRound size according to the source

SourcingClub was not involved in this transaction.

Onward Therapeutics completes a Series B round of NT$900m (around $28m). The company develops cancer drugs targeting resistance, and alongside existing investors, new institutional investors also participate.

In context

In November 2026 it is the 25th of 25 deals in Healthcare on the Deal-Radar.

Deal-Radar editorial team · responsible:

Source from the same day: startupticker.ch , 19 Nov 2026

Who was involved.

Lead investor
CDIB Capital Healthcare Ventures
Target
Onward Therapeutics, Taipei
Type
Funding round
Country
TW
Source dated
19/11/2026
Round size
$900m, according to the source

Deal-Radar no. 47-106 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits

We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.

November 2026 on the Deal-Radar.

40 of 269 deals so far are of the type Funding round.

  1. Strategic104
  2. Add-on41
  3. Funding round40
  4. Carve-out29
  5. Buy-out16
  6. Insolvency12
  7. Minority stake11
  8. Secondary8
  9. Succession6
  10. Merger2

New deals every day. By email on Mondays.

All deals of the previous week in one email, with source and adviser.

Weekly email every Monday, in German.

Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 19 November 2026.